Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8900609 | 0.92 | EDNRA (0.48) | EDNRAEDNRB | |
| SCHEMBL9023703 | 0.91 | EDNRA (0.48) | EDNRAEDNRB | |
| SCHEMBL8902917 | 0.88 | EDNRA (0.50) | EDNRAEDNRB | |
| SCHEMBL8902860 | 0.88 | EDNRA (0.52) | EDNRAEDNRB | |
| SCHEMBL8902261 | 0.88 | EDNRA (0.52) | EDNRAEDNRB | |
| SCHEMBL8902284 | 0.86 | EDNRA (0.49) | EDNRAEDNRB | |
| SCHEMBL8856691 | 0.84 | EDNRA (0.62) | EDNRAEDNRB | |
| SCHEMBL9023321 | 0.83 | EDNRA (0.47) | EDNRAEDNRB | |
| SCHEMBL8902594 | 0.83 | EDNRA (0.47) | EDNRAEDNRB | |
| SCHEMBL8900589 | 0.82 | EDNRA (0.65) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0676959-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM CORP (US) | 1996-01-03 | — | — | EP | claimed |
| EP-0676959-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-18 | — | — | EP | claimed |
| WO-1994014434-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | claimed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| US-5686481-A | INDOLE DERIVATIVES; TREATING HYPERTENSION, RENAL FAILURE, CEREBROVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0676959-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM CORP (US) | 1996-01-03 | — | — | EP | disclosed |
| EP-0676959-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994014434-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | EDNRA 2/4885EDNRB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.